The valuation of R&D expenditures in Japan

被引:14
|
作者
Nguyen, Pascal [1 ]
Nivoix, Sophie [2 ]
Noma, Mikiharu [3 ]
机构
[1] Univ Technol Sydney, Sch Finance & Econ, Sydney, NSW 2007, Australia
[2] Univ Poitiers, Fac Law & Social Sci, Poitiers, France
[3] Hitotsubashi Univ, Grad Sch Int Corp Strategy, Tokyo, Japan
来源
ACCOUNTING AND FINANCE | 2010年 / 50卷 / 04期
关键词
R&D expenses; Reporting biases; Market valuation; Mispricing; Abnormal returns; G14; STOCK RETURNS; MOBILITY BARRIERS; MARKET VALUE; QUALITY; FIRMS; RISK;
D O I
10.1111/j.1467-629X.2010.00345.x
中图分类号
F8 [财政、金融];
学科分类号
0202 ;
摘要
The difficulty to measure the long-term benefits of R&D expenditures and the distortions induced by R&D accounting suggest that R&D-intensive firms could be undervalued. Using several methods commonly applied to detect the abnormal returns associated with mispricing, we find little evidence that the value of R&D investments has been underestimated in the Japanese stock market. Given that R&D accounting rules in Japan are similar to those in United States, the results appear to reject the hypothesis that accounting biases are the cause of the undervaluation of R&D investments observed in the United States.
引用
收藏
页码:899 / 920
页数:22
相关论文
共 50 条
  • [1] The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan
    Jörg C. Mahlich
    Thomas Roediger-Schluga
    [J]. Review of Industrial Organization, 2006, 28 : 145 - 164
  • [2] The determinants of pharmaceutical R&D expenditures: Evidence from Japan
    Mahlich, JC
    Roediger-Schluga, T
    [J]. REVIEW OF INDUSTRIAL ORGANIZATION, 2006, 28 (02) : 145 - 164
  • [3] Characteristics of R&D expenditures in Japan's pharmaceutical industry
    Nivoix, Sophie
    Nguyen, Pascal
    [J]. ASIA PACIFIC BUSINESS REVIEW, 2012, 18 (02) : 225 - 240
  • [4] Stock market valuation of R&D expenditures-The role of corporate governance
    Chan, Konan
    Chen, Hung-Kun
    Hong, Li-Hong
    Wang, Yanzhi
    [J]. PACIFIC-BASIN FINANCE JOURNAL, 2015, 31 : 78 - 93
  • [5] CAPITALIZING R&D EXPENDITURES
    Diewert, W. Erwin
    Huang, Ning
    [J]. MACROECONOMIC DYNAMICS, 2011, 15 (04) : 537 - 564
  • [6] Valuation of options in R&D
    Pizmoht, P.
    Polajnar, A.
    Palcic, I.
    [J]. ANNALS OF DAAAM FOR 2005 & PROCEEDINGS OF THE 16TH INTERNATIONAL DAAAM SYMPOSIUM: INTELLIGENT MANUFACTURING & AUTOMATION: FOCUS ON YOUNG RESEARCHES AND SCIENTISTS, 2005, : 303 - 304
  • [7] R&D expenditures and CEO compensation
    Cheng, SJ
    [J]. ACCOUNTING REVIEW, 2004, 79 (02): : 305 - 328
  • [8] Creditor Rights and R&D Expenditures
    Seifert, Bruce
    Gonenc, Halit
    [J]. CORPORATE GOVERNANCE-AN INTERNATIONAL REVIEW, 2012, 20 (01) : 3 - 20
  • [9] Global Biomedical R&D Expenditures
    Young, Alison J.
    Terry, Robert F.
    Rottingen, John-Arne
    Viergever, Roderik F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (25): : 2451 - 2451
  • [10] The valuation of corporate R&D expenditures: Evidence from investment opportunities and free cash flow
    Szewczyk, SH
    Tsetsekos, GP
    Zantout, Z
    [J]. FINANCIAL MANAGEMENT, 1996, 25 (01) : 105 - &